Table 3.
Adverse events of atezolizumab plus bevacizumab treatment.
| n(%) | Links (n=31) | |
|---|---|---|
| Any grade | Grade 3 or 4 | |
| Hypertension | 4 (12.9) | 0 |
| Fatigue | 2 (6.4) | 0 |
| Proteinuria | 11 (35.4) | 7 (22.5) |
| AST increase | 7 (22.5) | 5 (16.1) |
| Pruritus | 0 | |
| Diarrhea | 0 | 0 |
| Decreased appetite | 1 (3.2) | 0 |
| Pyrexia | 2(6.4) | 0 |
| AL T increase | 4 (12.9) | 3 (9.6) |
| Constipation | 0 | 0 |
| Blood bilirubin increase | 4 (12.9) | 2 (6.4) |
| Rash | 0 | 0 |
| Abdominal pain | 1 (3.2) | 0 |
| Weight decrease | 0 | 0 |
| Asthenia | 1 (3.2) | 0 |
| Infusion reaction | 0 | 0 |
| HFS | 2 (6.4) | 0 |
| HCC rupture | 2 (6.4) | 2 (6.4) |
| Hepatic encephalopathy | 2 (6.4) | 1 (3.2) |
| Ascites | 3 (9.6) | 2 (6.4) |
| Stevens–Johnson syndrome | 1 (3.2) | 1 (3.2) |
| Stomatitis | 1 (3.2) | 0 |
| Adrenal insufficiency | 1 (3.2) | 0 |
Data are expressed as number (%).
ALT = alanine transaminase, HCC = hepatocellular carcinoma, HFS = hand-foot syndrome.